Autoimmune Encephalitis in Late-Onset Seizures: When to Suspect and How to Treat

Marie Süße; Maria Zank; Viola von Podewils; Felix von Podewils

doi:10.3389/fneur.2021.633999

Autoimmune Encephalitis in Late-Onset Seizures: When to Suspect and How to Treat

Front Neurol. 2021 Apr 7:12:633999. doi: 10.3389/fneur.2021.633999. eCollection 2021.

Authors

Marie Süße¹, Maria Zank¹, Viola von Podewils¹, Felix von Podewils¹

Affiliation

¹ Department of Neurology, Epilepsy Center, University Medicine Greifswald, Greifswald, Germany.

Abstract

Objective: This study was conducted to elucidate prevalence, clinical features, outcomes, and best treatment in patients with late-onset seizures due to autoimmune encephalitis (AE). Methods: This is a single-institution prospective cohort study (2012-2019) conducted at the Epilepsy Center at the University of Greifswald, Germany. A total of 225 patients aged ≥50 years with epileptic seizures were enrolled and underwent an MRI/CT scan, profiling of neural antibodies (AB) in serum and cerebrospinal fluid (CSF), and neuropsychological testing. On the basis of their work-up, patients were categorized into the following three cohorts: definite, suspected, or no AE. Patients with definite and suspected AE were subsequently treated with immunosuppressive therapy (IT) and/or anti-seizure drug (ASD) therapy and were followed up (FU) regarding clinical and seizure outcome. Results: Of the 225 patients, 17 (8%) fulfilled the criteria for definite or suspected AE according to their AB profile and MRI results. Compared with patients with no evidence of AE, those with AE were younger (p = 0.028), had mesial temporal neuropsychological deficits (p = 0.001), frequently had an active or known malignancy (p = 0.006) and/or a pleocytosis (p = 0.0002), and/or had oligoclonal bands in CSF (p = 0.001). All patients with follow-up became seizure-free with at least one ASD. The Modified Rankin scale (mRS) at hospital admission was low for patients with AE (71% with mRS ≤2) and further decreased to 60% with mRS ≤2 at last FU. Significance: AE is an important etiology in late-onset seizures, and seizures may be the first symptom of AE. Outcome in non-paraneoplastic AE was favorable with ASD and IT. AB testing in CSF and sera, cerebral MRI, CSF analysis, and neuropsychological testing for mesial temporal deficits should be part of the diagnostic protocol for AE following late-onset seizures.

Keywords: autoimmune encephalitis; epilepsy of unknown origin; late onset seizures; neural antibodies; outcome.